Satellos Bioscience Appoints Pharma Veteran Stephanie Brown to Board of Directors

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) has appointed Stephanie Brown to its Board of Directors. Brown brings over 30 years of biopharma industry experience, with expertise in product commercialization and organizational transformation. She has held executive positions at major pharmaceutical companies including Santhera, Ipsen, Merck, Genentech, Biogen, Takeda, and Novartis, where she managed high-value product portfolios and led successful product launches. Her experience includes the commercialization of Aimovig, a breakthrough migraine prevention therapy. Currently, she serves on the Board of Directors for Resilia, Inc.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) ha nominato Stephanie Brown nel suo Consiglio di Amministrazione. Brown porta con sé oltre 30 anni di esperienza nell’industria biofarmaceutica, con competenze nella commercializzazione dei prodotti e nella trasformazione organizzativa. Ha ricoperto posizioni dirigenziali in importanti aziende farmaceutiche, tra cui Santhera, Ipsen, Merck, Genentech, Biogen, Takeda e Novartis, dove ha gestito portafogli di prodotti di alta valore e ha guidato lanci di prodotto di successo. La sua esperienza include la commercializzazione di Aimovig, una terapia innovativa per la prevenzione dell’emicrania. Attualmente, fa parte del Consiglio di Amministrazione di Resilia, Inc.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) ha designado a Stephanie Brown para su Junta Directiva. Brown cuenta con más de 30 años de experiencia en la industria biofarmacéutica, con especialización en la comercialización de productos y transformación organizativa. Ha ocupado puestos ejecutivos en importantes compañías farmacéuticas, incluyendo Santhera, Ipsen, Merck, Genentech, Biogen, Takeda y Novartis, donde gestionó carteras de productos de alto valor y lideró lanzamientos exitosos. Su experiencia incluye la comercialización de Aimovig, una terapia revolucionaria para la prevención de migrañas. Actualmente, forma parte de la Junta Directiva de Resilia, Inc.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF)가 Stephanie Brown을 이사회의 이사로 임명했습니다. 브라운은 30년 이상의 생명과학 산업 경험을 보유하고 있으며, 제품 상용화 및 조직 변화에 대한 전문성을 가지고 있습니다. 그녀는 Santhera, Ipsen, Merck, Genentech, Biogen, Takeda 및 Novartis와 같은 주요 제약 회사에서 임원직을 역임하며 고부가가치 제품 포트폴리오를 관리하고 성공적인 제품 출시에 기여했습니다. 그녀의 경험에는 편두통 예방 치료제인 Aimovig의 상용화가 포함되어 있습니다. 현재 그녀는 Resilia, Inc.의 이사회의 이사로 활동하고 있습니다.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) a nommé Stephanie Brown au sein de son Conseil d’administration. Brown possède plus de 30 ans d’expérience dans l’industrie biopharmaceutique, avec une expertise en commercialisation de produits et transformation organisationnelle. Elle a occupé des postes de direction dans de grandes entreprises pharmaceutiques, notamment Santhera, Ipsen, Merck, Genentech, Biogen, Takeda et Novartis, où elle a géré des portefeuilles de produits de grande valeur et a dirigé des lancements de produits réussis. Son expérience inclut la commercialisation d’Aimovig, une thérapie révolutionnaire pour la prévention de la migraine. Actuellement, elle siège au Conseil d’administration de Resilia, Inc.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) hat Stephanie Brown in seinen Vorstand berufen. Brown bringt über 30 Jahre Erfahrung in der Bio-Pharma-Industrie mit, mit Fachwissen in der Produktkommerzialisierung und organisatorischen Transformation. Sie hatte leitende Positionen bei großen Pharmaunternehmen inne, darunter Santhera, Ipsen, Merck, Genentech, Biogen, Takeda und Novartis, wo sie hochpreisige Produktportfolios verwaltete und erfolgreiche Produkteinführungen leitete. Ihre Erfahrung umfasst die Kommerzialisierung von Aimovig, einer bahnbrechenden Therapie zur Vorbeugung von Migräne. Derzeit ist sie im Vorstand von Resilia, Inc. tätig.

Positive

• Appointment of seasoned executive with 30+ years of biopharma industry experience
• Strong expertise in rare disease commercialization and product launches
• Extensive leadership experience with major pharmaceutical companies
• Track record of successful product commercialization with revenues reaching billions

11/14/2024 – 07:00 AM

TORONTO–(BUSINESS WIRE)–
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the appointment of Stephanie Brown to its Board of Directors. Ms. Brown brings over 30 years of biopharma industry experience, having held numerous executive roles contributing to groundbreaking achievements in product commercialization and organizational transformation.

“Stephanie is a recognized leader in the biopharma space and has led multiple successful product launches for biologics and small molecules, particularly within the rare diseases sector,” said Frank Gleeson, Co-founder and CEO of Satellos Bioscience. “Her exceptional experience in building and scaling biopharma companies, particularly in rare and specialty disease markets, aligns well with Satellos’ mission to innovate for patients with serious muscle diseases. Her expertise will be invaluable as we advance transformative treatments and position the Company for future growth.”

Over her career, Ms. Brown’s contributions have spanned business development, portfolio planning, and corporate optimization with revenues reaching billions. Ms. Brown has held senior leadership roles, including President, North America for Santhera Pharmaceuticals, where she oversaw operations and strategic objectives, and Head of Rare Diseases at Ipsen Biopharmaceuticals, where she directed the commercialization strategy for in-line and launch brands. She has also been a vital member of executive teams at top global firms, including Merck, Genentech, Biogen, Takeda Pharmaceuticals, and Novartis, where she managed high-value product portfolios and led launches for multiple specialty and rare disease treatments, including the successful launch of Aimovig, a breakthrough migraine prevention therapy.

Currently, Stephanie serves on the Board of Directors for Resilia, Inc. She has previously held board positions with ObsEva and the Biotechnology Innovation Organization (BIO), among others, contributing her expertise to the advancement of biotech innovations and patient-centered solutions.

About Satellos Bioscience Inc.

Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (DMD). Satellos has generated a significant body of preclinical evidence in DMD to support that correcting muscle stem cell polarity with SAT-3247 has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has been damaged. The Company’s lead drug candidate SAT-3247 is currently in clinical development as a potential disease-modifying treatment DMD. Additionally, Satellos is leveraging its breakthrough research in muscle stem cell polarity and proprietary discovery platform MyoReGenX™, to identify degenerative muscle diseases where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit www.satellos.com.

Notice on Forward-Looking Statements

This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential of our approach in other degenerative muscle diseases or in muscle injury or trauma; the general benefits of modulating stem cell polarity by administering small molecule drugs; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; the utility of regenerating muscle by modulating polarity; adoption of Satellos’ approach by the medical community; and Satellos’ technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective” , “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the “Risk Factors” section of Satellos’ Annual Information Form dated March 26, 2024 (which is located on Satellos’ profile at www.sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward- looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise

View source version on businesswire.com:

Investors: Liz Williams, CFO, ir@satellos.com

Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091

Source: Satellos Bioscience Inc.

FAQ

Who is the new Board Director appointed to Satellos Bioscience (MSCLF)?

Stephanie Brown, a biopharma executive with over 30 years of industry experience, has been appointed to Satellos Bioscience’s Board of Directors.

What is Stephanie Brown’s experience in the pharmaceutical industry before joining Satellos (MSCLF)?

Brown has held executive roles at major pharmaceutical companies including Santhera, Ipsen, Merck, Genentech, Biogen, Takeda, and Novartis, managing high-value product portfolios and leading successful product launches.

What notable product launch has Stephanie Brown been involved with before joining Satellos (MSCLF)?

Brown led the successful launch of Aimovig, a breakthrough migraine prevention therapy, during her career in the pharmaceutical industry.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source